| Name | Title | Contact Details |
|---|
Tristan Associates c/o Breast Center is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Open MRI of Georgia is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Deep Expertise, Broad Reach Versiti is a strategic affiliation of successful healthcare organizations whose vision is to improve the health of patients as the national leader in innovative transfusion solutions for healthcare systems. Everyone in our nation’s healthcare system is seeking new and better ways to provide high-quality patient care at an affordable cost. Organizations that offer vital resources must also look at new models of operating that will continually improve patient outcomes, increase the quality of service, and reduce the cost of healthcare. Working together, Versiti offers hospitals a more comprehensive range of services, including transfusion medicine, transplantation, stem cell and cellular therapies, hematology, oncology and genomics. We are passionate about improving the lives of our patients and hospital partners. We apply our deep expertise in blood-related service to solve the toughest challenges Our expertise and resources lead to new products, solutions and services to meet patient and hospital needs. We Believe: By bringing together the industry’s best and brightest, the depth and breadth of our expertise sets us apart Our relationships with donors, patients and hospital partners inspire everything we do We offer best-in-class products and services Our work sets new standards for quality, efficiency and care Our approach will reshape our industry and create new ways to help people and communities thrive
CareDynamix is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.